Evolocumab treatment is associated with early and sustained reductions in low-density cholesterol (LDL-C) over 30 months: final results from the pan-European observational HEYMANS registry

Back

ESC Professional Premium Access

Evolocumab treatment is associated with early and sustained reductions in low-density cholesterol (LDL-C) over 30 months: final results from the pan-European observational HEYMANS registry

Session: Lipid-lowering by PCSK9 modulation: what’s new?

Topic: Lipid-Lowering Agents

Speaker: Professor K. Ray (London, GB)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

91 presentations

16 followers

4 more presentations in this session

PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular disease

Speaker: Doctor D. Kannenkeril (Erlangen, DE)

Impact of alirocumab added to high-intensity statin therapy on platelet function in AMI patients: a pre-specified substudy of the randomized, placebo-controlled PACMAN-AMI trial

Speaker: Doctor L. Raber (Bern, CH)

Low-density lipoprotein cholesterol reduction with evolocumab and its use in clinical practice: evidence from swedish national register data

Speaker: Professor M. Svensson (Uppsala, SE)

High individual variability in LDL-reductions after inclisiran administration in a "real-world setting"

Speaker: Professor O. Weingaertner (Jena, DE)

Access the full session

Lipid-lowering by PCSK9 modulation: what’s new?

Speakers: Professor K. Ray, Doctor D. Kannenkeril, Doctor L. Raber, Professor M. Svensson, Professor O. Weingaertner

Access

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources